Companies › GC Cell
2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 3; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Immuncell-LC Autologous activated T lymphocyte | – | Phase 3 | Pancreatic Ductal Adenocarcinoma | Dec 2026 |
| GCC2005 CAR-NK cell therapy | – | Phase 1 | Lymphoma, T-Cell | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04969731 | Immuncell-LC | Phase 3 | Pancreatic Ductal Adenocarcinoma | Oncology | Dec 2026 |
| NCT06699771 | GCC2005 | Phase 1 | Lymphoma, T-Cell | Oncology | Aug 2027 |
No annotated target.
–
GeneQuantum Healthcare (Suzhou) Sellas Life Sciences Group Kura Oncology Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) RayzeBio
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.